Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals. As of December 31, 2016, it had partnerships and license agreements with over 85 pharmaceutical and biotechnology companies, and over 140 various programs under license with it were in various stages of commercialization and development. It has contributed research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and low blood platelets, among others.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology & Medical Research
- Sub-Industry: Biotechnology
- Symbol: NASDAQ:LGND
- CUSIP: 53220K50
- Web: www.ligand.com
- Market Cap: $2.85927 billion
- Outstanding Shares: 21,053,000
- 50 Day Moving Avg: $128.78
- 200 Day Moving Avg: $116.74
- 52 Week Range: $87.50 - $138.49
Sales & Book Value:
- Trailing P/E Ratio: 329.07
- Foreward P/E Ratio: 37.86
- P/E Growth: 1.44
- Annual Revenue: $117.07 million
- Price / Sales: 24.38
- Book Value: $19.45 per share
- Price / Book: 6.97
- EBIDTA: $60.55 million
- Net Margins: 7.39%
- Return on Equity: 5.05%
- Return on Assets: 2.94%
- Debt-to-Equity Ratio: 0.06%
- Current Ratio: 0.87%
- Quick Ratio: 0.84%
- Average Volume: 251,136 shs.
- Beta: 0.99
- Short Ratio: 28.6
Frequently Asked Questions for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
What is Ligand Pharmaceuticals Incorporated's stock symbol?
Ligand Pharmaceuticals Incorporated trades on the NASDAQ under the ticker symbol "LGND."
How were Ligand Pharmaceuticals Incorporated's earnings last quarter?
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) released its quarterly earnings data on Monday, August, 7th. The company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.42. The firm had revenue of $28 million for the quarter, compared to analyst estimates of $24.40 million. Ligand Pharmaceuticals Incorporated had a return on equity of 5.05% and a net margin of 7.39%. The business's revenue for the quarter was up 43.6% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.50 earnings per share. View Ligand Pharmaceuticals Incorporated's Earnings History.
When will Ligand Pharmaceuticals Incorporated make its next earnings announcement?
Where is Ligand Pharmaceuticals Incorporated's stock going? Where will Ligand Pharmaceuticals Incorporated's stock price be in 2017?
5 equities research analysts have issued 12 month price targets for Ligand Pharmaceuticals Incorporated's shares. Their forecasts range from $104.00 to $160.00. On average, they expect Ligand Pharmaceuticals Incorporated's share price to reach $135.17 in the next twelve months. View Analyst Ratings for Ligand Pharmaceuticals Incorporated.
What are analysts saying about Ligand Pharmaceuticals Incorporated stock?
Here are some recent quotes from research analysts about Ligand Pharmaceuticals Incorporated stock:
- 1. HC Wainwright analysts commented, "core long term holding" for investors. The firm's Joseph Pantginis initiated coverage of the biopharmaceutical company with a Buy rating and $150 price target, mostly due to the company's business model.Ligand seeks out value-based acquisitions of companies and technologies that have led to both current and anticipated revenue streams, Pantginis commented in his initiation note. This has also resulted in the company's reputation of reporting sustained profitability.Ligand is also an early pioneer of contingent value rights for its acquisitions, the analyst continued. As such, earnings growth is supported by the company's increasing royalty streams that are also a "significant spreading out of risk" (9/5/2017)
- 2. According to Zacks Investment Research, "Ligand’s Captisol formulation technology has resulted in partnerships with several leading drug companies like Novartis and Amgen that provide it with funds in the form of milestone and royalty payments. However, the company derives a substantial portion of its revenues from royalties associated with the sales of two products – Promacta and Kyprolis. Any setback related to either of these two products could have a substantial impact on the company’s results. Notably, Ligand obtains Captisol from a single supplier. Hence any interruption in the supply of Captisol would have an adverse effect on the company’s results. Shares of Ligand have outperformed the broader industry in the last one year. Estimates have been stable lately ahead of the company’s Q2 earnings release. The company has positive record of earnings surprises in recent quarters." (7/11/2017)
Who are some of Ligand Pharmaceuticals Incorporated's key competitors?
Some companies that are related to Ligand Pharmaceuticals Incorporated include INC Research Holdings (INCR), Exact Sciences Corporation (EXAS), Galapagos NV (GLPG), Charles River Laboratories International (CRL), United Therapeutics Corporation (UTHR), PRA Health Sciences (PRAH), ACADIA Pharmaceuticals (ACAD), Bio-Techne Corp (TECH), PAREXEL International Corporation (PRXL), FibroGen (FGEN), Puma Biotechnology (PBYI), Nektar Therapeutics (NKTR), WuXi PharmaTech (Cayman) (WX), Portola Pharmaceuticals (PTLA), Blueprint Medicines Corporation (BPMC), Sage Therapeutics (SAGE), Ironwood Pharmaceuticals (IRWD) and Intrexon Corporation (XON).
Who are Ligand Pharmaceuticals Incorporated's key executives?
Ligand Pharmaceuticals Incorporated's management team includes the folowing people:
- Matthew W. Foehr, President, Chief Operating Officer
- John L. Higgins, Chief Executive Officer, Director
- Matthew E. Korenberg, Chief Financial Officer, Vice President - Finance
- Charles S. Berkman J.D., Vice President, General Counsel, Secretary
- John W. Kozarich, Non-Executive Independent Chairman of the Board
- Nancy Ryan Gray, Director
- Jason M. Aryeh, Independent Director
- Todd C. Davis, Independent Director
- John L. LaMattina Ph.D., Independent Director
Who owns Ligand Pharmaceuticals Incorporated stock?
Ligand Pharmaceuticals Incorporated's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (12.78%), William Blair Investment Management LLC (8.45%), Vanguard Group Inc. (8.30%), State Street Corp (3.86%), Victory Capital Management Inc. (3.23%) and Janus Henderson Group PLC (2.83%). Company insiders that own Ligand Pharmaceuticals Incorporated stock include Charles S Berkman, Jason Aryeh, John L Higgins, John W Kozarich, Matthew W Foehr and Melanie J Herman. View Institutional Ownership Trends for Ligand Pharmaceuticals Incorporated.
Who sold Ligand Pharmaceuticals Incorporated stock? Who is selling Ligand Pharmaceuticals Incorporated stock?
Ligand Pharmaceuticals Incorporated's stock was sold by a variety of institutional investors in the last quarter, including AJO LP, State of New Jersey Common Pension Fund D, State Street Corp, FMR LLC, Elk Creek Partners LLC, Columbia Partners L L C Investment Management, Principal Financial Group Inc. and Prudential Financial Inc.. Company insiders that have sold Ligand Pharmaceuticals Incorporated stock in the last year include Charles S Berkman, Jason Aryeh, John L Higgins and Matthew W Foehr. View Insider Buying and Selling for Ligand Pharmaceuticals Incorporated.
Who bought Ligand Pharmaceuticals Incorporated stock? Who is buying Ligand Pharmaceuticals Incorporated stock?
Ligand Pharmaceuticals Incorporated's stock was bought by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Russell Investments Group Ltd., Macquarie Group Ltd., Castleark Management LLC, Royal Bank of Canada, BlackRock Inc., Rice Hall James & Associates LLC and Tygh Capital Management Inc.. View Insider Buying and Selling for Ligand Pharmaceuticals Incorporated.
How do I buy Ligand Pharmaceuticals Incorporated stock?
Shares of Ligand Pharmaceuticals Incorporated can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Ligand Pharmaceuticals Incorporated's stock price today?
MarketBeat Community Rating for Ligand Pharmaceuticals Incorporated (NASDAQ LGND)MarketBeat's community ratings are surveys of what our community members think about Ligand Pharmaceuticals Incorporated and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
One share of Ligand Pharmaceuticals Incorporated stock can currently be purchased for approximately $135.55.
Consensus Ratings for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Ratings Breakdown: ||1 Hold Rating, 4 Buy Ratings|
|Consensus Rating:||Buy (Score: 2.80)|
|Consensus Price Target: ||$135.17 (0.28% downside)|
Analysts' Ratings History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
(Data available from 9/23/2015 forward)
|Date||Firm||Action||Rating||Price Target||Impact on Share Price||Details|
|9/5/2017||HC Wainwright||Reiterated Rating||Buy -> Buy||$150.00||Medium|
|8/9/2017||Stephens||Reiterated Rating||Overweight||$125.00 -> $137.00||Low|
|8/8/2017||Deutsche Bank AG||Boost Price Target||Hold||$103.00 -> $104.00||High|
|8/8/2017||Roth Capital||Boost Price Target||Buy||$120.00 -> $135.00||High|
|9/28/2016||CJS Securities||Lower Price Target||Outperform||$130.00 -> $125.00||N/A|
|10/5/2016||Craig Hallum||Boost Price Target||$150.00 -> $160.00||N/A|
Earnings History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)Earnings History by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ LGND)
(Data available from 1/1/2011 forward)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|11/2/2017|| || || || || || || || |
|8/7/2017||Q2 2017||$0.25||$0.67||$24.40 million||$28.00 million||View||Listen|
|5/9/2017||Q1 2017||$0.55||$0.39||$30.25 million||$29.27 million||View||Listen|
|2/23/2017||Q416||$1.19||($0.15)||$40.34 million||$38.20 million||View||N/A|
|11/3/2016||Q316||$0.59||$0.62||$23.64 million||$21.62 million||View||N/A|
|8/4/2016||Q216||$0.40||$0.50||$18.12 million||$19.50 million||View||N/A|
|5/4/2016||Q116||$0.67||$0.97||$26.45 million||$29.60 million||View||N/A|
|2/10/2016||Q415||$0.51||$0.66||$24.71 million||$21.20 million||View||Listen|
|11/9/2015||Q315||$0.42||$0.56||$17.80 million||$17.70 million||View||N/A|
|8/4/2015||Q215||$0.40||$1.63||$17.00 million||$18.42 million||View||N/A|
|5/11/2015||Q115||$0.12||$0.33||$13.50 million||$14.60 million||View||Listen|
|2/9/2015||Q414||$0.48||$0.48||$23.88 million||$23.00 million||View||N/A|
|10/27/2014||Q314||$0.21||$0.19||$14.60 million||$15.00 million||View||Listen|
|8/4/2014||Q214||$0.14||$0.24||$9.73 million||$10.60 million||View||N/A|
|5/7/2014||Q114||$0.25||$0.35||$13.63 million||$16.00 million||View||N/A|
|2/11/2014||Q413||$0.19||$0.35||$13.72 million||$14.70 million||View||N/A|
|10/30/2013||Q213||$0.07||$0.12||$10.81 million||$13.00 million||View||N/A|
|8/1/2013||Q2 2013||$0.06||$0.07||$9.48 million||$9.58 million||View||N/A|
|5/8/2013||Q1 2013||$0.09||$0.16||$10.00 million||$11.70 million||View||N/A|
|2/13/2013||Q4 2012||$0.19||$12.90 million||$13.60 million||View||N/A|
|11/5/2012||Q312||$0.04||($0.01)||$8.40 million||$6.40 million||View||N/A|
Earnings Estimates for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
2017 EPS Consensus Estimate: $2.60
(Data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Insider Ownership Percentage: 14.70%Insider Trades by Quarter for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Details|
|9/5/2017||John L Higgins||CEO||Sell||5,000||$130.00||$650,000.00|| |
|8/23/2017||Jason Aryeh||Director||Sell||2,000||$127.99||$255,980.00|| |
|8/9/2017||Charles S Berkman||VP||Sell||18,625||$126.96||$2,364,630.00|| |
|8/9/2017||Matthew W Foehr||Insider||Sell||6,100||$127.51||$777,811.00|| |
|8/8/2017||John L Higgins||CEO||Sell||5,483||$125.00||$685,375.00|| |
|6/21/2017||John L Higgins||CEO||Sell||4,666||$120.00||$559,920.00|| |
|6/9/2017||John L Higgins||CEO||Sell||12,000||$114.87||$1,378,440.00|| |
|5/12/2017||Jason Aryeh||Director||Sell||37,247||$110.76||$4,125,477.72|| |
|5/12/2017||Matthew W Foehr||Insider||Sell||5,621||$112.20||$630,676.20|| |
|3/20/2017||John L Higgins||CEO||Sell||4,000||$109.10||$436,400.00|| |
|3/2/2017||Matthew W Foehr||Insider||Sell||6,879||$103.39||$711,219.81|| |
|2/28/2017||Jason Aryeh||Director||Sell||32,000||$106.35||$3,403,200.00|| |
|11/25/2016||Jason Aryeh||Director||Sell||18,479||$107.31||$1,982,981.49|| |
|11/18/2016||Jason Aryeh||Director||Sell||6,330||$105.28||$666,422.40|| |
|9/22/2016||John L Higgins||CEO||Sell||3,000||$117.34||$352,020.00|| |
|9/7/2016||John W Kozarich||Director||Sell||1,000||$115.00||$115,000.00|| |
|9/1/2016||John W Kozarich||Director||Sell||1,666||$105.40||$175,596.40|| |
|8/1/2016||John W Kozarich||Director||Sell||1,000||$137.57||$137,570.00|| |
|7/1/2016||John W Kozarich||Director||Sell||1,000||$121.40||$121,400.00|| |
|6/1/2016||John W Kozarich||Director||Sell||1,000||$117.42||$117,420.00|| |
|5/18/2016||Melanie J Herman||Director||Sell||334||$120.50||$40,247.00|| |
|5/6/2016||Jason Aryeh||Director||Sell||25,000||$119.20||$2,980,000.00|| |
|5/2/2016||John W Kozarich||Director||Sell||1,000||$121.57||$121,570.00|| |
|4/6/2016||John W Kozarich||Director||Sell||5,000||$115.00||$575,000.00|| |
|3/17/2016||Matthew W Foehr||COO||Sell||6,400||$96.70||$618,880.00|| |
|3/8/2016||Jason Aryeh||Director||Sell||6,129||$101.18||$620,132.22|| |
|3/7/2016||John L Higgins||CEO||Sell||10,833||$102.47||$1,110,057.51|| |
|1/20/2016||John W. Kozarich||Director||Sell||1,666||$94.94||$158,170.04|| |
|11/11/2015||Melanie J. Herman||Director||Sell||7,719||$101.00||$779,619.00|| |
|8/17/2015||David M Knott||Director||Sell||4,000||$95.98||$383,920.00|| |
|8/13/2015||David M Knott||Director||Sell||49,800||$96.26||$4,793,748.00|| |
|7/10/2015||Charles S Berkman||VP||Sell||14,067||$99.14||$1,394,602.38|| |
|6/26/2015||Matthew W Foehr||COO||Sell||12,500||$100.97||$1,262,125.00|| |
|6/22/2015||Matthew W Foehr||COO||Sell||23,046||$96.45||$2,222,786.70|| |
|6/10/2015||Melanie J Herman||CFO||Sell||4,125||$93.50||$385,687.50|| |
|6/9/2015||John L Higgins||CEO||Sell||10,000||$92.88||$928,800.00|| |
|6/4/2015||Jason Aryeh||Director||Sell||1,640||$92.68||$151,995.20|| |
|5/20/2015||Jason Aryeh||Director||Sell||9,240||$87.34||$807,021.60|| |
|5/14/2015||Nishan M Desilva||CFO||Sell||68,363||$83.91||$5,736,339.33|| |
|3/19/2015||Sunil Patel||Director||Sell||4,591||$74.42||$341,662.22|| |
|2/10/2015||Nishan M Desilva||VP||Sell||2,300||$56.34||$129,582.00|| |
|10/15/2014||John W Kozarich||Director||Buy||2,000||$45.68||$91,360.00|| |
|10/9/2014||Jason Aryeh||Director||Buy||11,000||$42.99||$472,890.00|| |
|8/15/2014||John L Higgins||CEO||Buy||1,000||$54.97||$54,970.00|| |
|6/9/2014||Melanie J Herman||Director||Sell||1,100||$69.68||$76,648.00|| |
|5/27/2014||Charles S Berkman||VP||Sell||7,166||$66.90||$479,405.40|| |
|3/25/2014||Bvf Partners P/Il||Insider||Sell||78,226||$70.09||$5,482,860.34|| |
|3/19/2014||Todd Davis||Director||Sell||7,500||$79.57||$596,775.00|| |
|3/18/2014||John Lamattina||Director||Sell||5,000||$78.83||$394,150.00|| |
|2/20/2014||Bvf Partners P/Il||major shareholder||Sell||422,900||$73.81||$31,214,249.00|| |
|2/18/2014||David Knott||Director||Sell||41,900||$75.71||$3,172,249.00|| |
|2/14/2014||Jason Aryeh||Director||Sell||40,320||$76.44||$3,082,060.80|| |
|2/14/2014||Matthew Foehr||COO||Sell||22,500||$79.54||$1,789,650.00|| |
|12/12/2013||Matthew Foehr||COO||Sell||6,000||$53.40||$320,400.00|| |
|12/6/2013||John Sharp||CFO||Sell||6,000||$56.08||$336,480.00|| |
|10/18/2013||John L Higgins||CEO||Sell||10,000||$55.00||$550,000.00|| |
|9/23/2013||Bvf Partners P/Il||major shareholder||Sell||359,023||$44.50||$15,976,523.50|| |
|9/12/2013||David Knott||Director||Sell||160,000||$46.78||$7,484,800.00|| |
|8/30/2013||Charles Berkman||VP||Sell||28,323||$47.54||$1,346,475.42|| |
|8/16/2013||Charles Berkman||VP||Sell||14,583||$42.63||$621,673.29|| |
|8/16/2013||John Higgins||CEO||Sell||10,000||$42.85||$428,500.00|| |
|8/16/2013||John Sharp||CFO||Sell||7,500||$42.75||$320,625.00|| |
|6/28/2013||Matthew W Foehr||COO||Buy||1,059||$17.36||$18,384.24|| |
|5/10/2013||Charles S Berkman||VP||Sell||4,000||$26.66||$106,640.00|| |
|1/23/2013||Bvf Partners L P/Il||Major Shareholder||Buy||39,600||$19.78||$783,288.00|| |
|12/14/2012||Bvf Partners L P/Il||Major Shareholder||Buy||5,386||$18.63||$100,341.18|| |
|12/6/2012||Bvf Partners L P/Il||Major Shareholder||Buy||50,100||$17.94||$898,794.00|| |
|12/5/2012||John L Higgins||CEO||Buy||2,000||$18.03||$36,060.00|| |
|10/31/2012||Bvf Partners L P/Il||Major Shareholder||Buy||16,591||$15.19||$252,017.29|| |
|8/29/2012||David M Knott||Director||Buy||2,743||$16.36||$44,875.48|| |
Headline Trends for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Latest Headlines for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND)
Ligand Pharmaceuticals Incorporated (LGND) Chart for Saturday, September, 23, 2017